pharma · Weight management · Short Bowel Syndrome
Zealand Pharma
Zealand Pharma A/S
Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ven
Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Sydmarken 11, Søborg (Copenhagen), 2860, DK
- Founded
- 1998
- Employees
- 596
- Programs
- 18
- Drugs
- 20
- Patents
- 0
Glepaglutide 20.0 mg/mL
Phase 3 · small molecule · Short Bowel Syndrome
Glepaglutide 20.0 mg/mL for Short Bowel Syndrome is a Phase 3 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).
Internal code ZP1848-25009
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zealand Pharma A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Short Bowel Syndrome
- Status
- active
- Trials
- 1